Analytical Data
-
Gene name
Siglec-8
- Application
-
Alternative Names
Cytokine CX2
-
Species
Rat
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
F1LTN0
-
Expression Region
His23~Gln203
-
Molecular Weight
25kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Siglec-8, a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family, has garnered considerable attention in immunological research due to its role in regulating immune responses, particularly in the context of eosinophils, mast cells, and other hematopoietic cells. It is primarily expressed on the surface of these cells, where it functions as an inhibitory receptor, modulating inflammatory processes and mediating cell apoptosis. Elevated levels of Siglec-8 are often associated with allergic diseases, asthma, and various other immunological disorders. Research has shown that Siglec-8 engagement by its ligands leads to attenuation of immune activation and inflammation, presenting a potential therapeutic target for treating allergic and autoimmune diseases. The development of recombinant Siglec-8 proteins has been pivotal in elucidating its mechanisms of action and potential clinical applications. These studies aim to enhance our understanding of Siglec-8's role in immune regulation and to facilitate the design of novel therapeutic strategies that harness its functions, thereby potentially offering new avenues for intervention in allergic and inflammatory conditions. The ongoing exploration of Siglec-8's biology is expected to provide insights into its signaling pathways and interactions, paving the way for innovative treatments that leverage this receptor's unique properties.
